Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weight-based versus usual-dose enoxaparin for neonatal thrombosis
IRCT20220122053794N1Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enoxaparin in neonatal thrombosis (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Complete clot resolution, Duration of treatment and 3 more. Started Jan 2022; status: completed.
02
Drugs
enoxaparin
03
Conditions
neonatal thrombosis
Beyond the preview
Go deeper on IRCT20220122053794N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220122053794N1.